Tayla R. Penny

Tayla R. Penny

Auto-generated profile, based on publicly available information

Tayla R. Penny

The Ritchie Centre, Hudson Institute of Medical Research, Clayton, Victoria, Australia; Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Brain Research
Verified
Journal Article
Closed access
TPTayla R. Penny
Tayla R. Penny
YPYen Pham
Yen Pham
ASAmy E. Sutherland
Amy E. Sutherland
JMJamie G. Mihelakis
Jamie G. Mihelakis
Joohyung LeeJoohyung Lee
Joohyung Lee
CMCourtney McDonald
Courtney McDonald

1 July 2021 in Behavioural Brain Research
Verified
Journal Article
Closed access
TPTayla R. Penny
Tayla R. Penny
YPYen Pham
Yen Pham
ASAmy Sutherland
Amy Sutherland
MSMadeleine J. Smith
Madeleine J. Smith
Joohyung LeeJoohyung Lee
Joohyung Lee
CMCourtney McDonald
Courtney McDonald

4 February 2023 in Cytotherapy
Verified
Journal Article
Open access
LZLindsay Zhou
Lindsay Zhou
CMCourtney A. McDonald
Courtney A. McDonald
TYTamara Yawno
Tamara Yawno
TPTayla Penny
Tayla Penny
SMSuzanne L. Miller
Suzanne L. Miller
AMAtul Malhotra
Atul Malhotra
Umbilical cord blood (UCB)-derived cells show strong promise as a treatment for neonatal brain injury in pre-clinical models and early-phase clinical trials. Feasibility of UCB collection and autologous administration is reported for term infants, but data are limited for preterm infants. Here the authors assessed the feasibility of UCB-derived cell collection for autologous use in extremely preterm infants born at less than 28 weeks, a population with a high incidence of brain injury and subsequent neurodisability. In a prospective study at a tertiary hospital in Melbourne, Australia, UCB was collected from infants born at less than 28 weeks and processed to obtain total nucleated cells (TNCs), CD34+ cells, mononuclear cells and cell viability via fluorescence-activated cell sorting prior to cryopreservation. Feasibility was pre-defined as volume adequate for cryopreservation (>9 mL UCB collected) and >25 × 106 TNCs/kg retrieved. Thirty-eight infants (21 male, 17 female) were included in the study. Twenty-four (63.1%) were delivered via cesarean section, 30 (78.9%) received delayed cord clamping before collection and 11 (28.9%) were a multiple birth. Median (interquartile range [IQR]) gestational age was 26.0 weeks (24.5-27.5) and mean (standard deviation) birth weight was 761.5 g (221.5). Median (IQR) UCB volume collected was 19.1 mL/kg (10.5-23.5), median (IQR) TNC count was 105.2 × 106/kg (57.4-174.4), median (IQR) CD34+ cell count was 1.5 × 106/kg (0.6-2.1) and median (IQR) cell viability pre-cryopreservation was 95% (92.1-96.0). Feasibility of collection volume and cell count suitable for cell cryopreservation was achieved in 27 (71%) and 28 (73.6%) infants, respectively. UCB-derived cell collection adequate for cryopreservation and subsequent autologous reinfusion was achieved in 70% of extremely preterm infants. Extremely preterm UCB demonstrated a higher CD34+:TNC ratio compared with published full-term values. Recruitment to demonstrate safety of UCB cell administration in extremely premature infants is ongoing in the CORD-SAFE study (trial registration no. ACTRN12619001637134).